Earnings Call · Q1 FY2024·2024-05-08

Q1 24EPS +66.67%·Rev n/aQ4 23EPS -6.67%·Rev n/aQ3 23EPS +4.76%·Rev n/aQ2 23EPS +100.00%*·Rev n/a⚠ consensus missing

ACADIA PHARMACEUTICALS INC ACAD

Al Kildani — Host/Investor Relations

Steve Davis — Chief Executive Officer

Brendan Teehan — Chief Operating Officer

Kimberly Manhard — Senior Vice President, Clinical Development

Mark Schneyer — Chief Financial Officer

−11.2%1d on move date−11.8% vs SPY3d−11.4%5d−11.7%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ACAD calls or request research access.

More ACAD calls Browse calls Request research access